<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147078</url>
  </required_header>
  <id_info>
    <org_study_id>SI2019175</org_study_id>
    <nct_id>NCT04147078</nct_id>
  </id_info>
  <brief_title>Personalized DC Vaccine for Postoperative Cancer</brief_title>
  <official_title>Adjuvant Treatment in Cancer Patients With Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC)
      cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular
      carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to
      efficacy and adverse event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative patients with pathological confirmed locally advanced gastric cancer,
      hepatocellular carcinoma, non-small cell lung cancer and colorectal cancer with standard
      adjuvant treatment are enrolled. This is a prospective exploratory trial. Patients' tumor
      tissues are subsequent to whole exosome sequencing and possible neoantigens are identified.
      DC is in vitro primed with synthesized peptides. Both adverse events and responses are
      recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as the time from the surgery to the first documented disease recurrence or death (by any cause), whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Defined by the time between the date of randomization and the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events [Safety and Tolerability]</measure>
    <time_frame>3 months after the last administration of cells</time_frame>
    <description>Defined by treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <condition>Colon Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>cell_therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC vaccine subcutaneous administration</intervention_name>
    <description>subcutaneous administration</description>
    <arm_group_label>cell_therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma,
             non-small cell lung cancer, colorectal cancer who have undergone a curative resection
             or ablation

          -  Anticipated life time &gt; 3month

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

          -  Adequate organ functions

        Exclusion Criteria:

          -  Any evidence of tumor metastasis or co-existing malignant disease

          -  Tumor emergency

          -  Abnormal coagulation condition

          -  Contagious diseases, such as hepatitis B virus, hepatitis C virus, human
             immunodefficiency virus, tuberculosis infection

          -  Concomitant tumors

          -  Immunological co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qiu Li</last_name>
    <phone>+86 028-85422589</phone>
    <email>liqiu@scu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qiu Li</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiu Li, PhD</last_name>
      <phone>+86 028-85422589</phone>
      <email>liqiu@scu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qiu Li</last_name>
      <phone>+86 028-85422589</phone>
      <email>liqiu@scu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Zhen-Yu Ding</investigator_full_name>
    <investigator_title>Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University</investigator_title>
  </responsible_party>
  <keyword>Cell therapy</keyword>
  <keyword>safety</keyword>
  <keyword>clinical efficacy</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>locally advanced cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

